… squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the
combination of cisplatin and cetuximab… combination of cisplatin, cetuximab and VPA in recurrent/…

… with cetuximab for heavily pretreated patients with inoperable squamous cell carcinoma of
the head and neck… We demonstrate that a second course of RT combined with cetuximab is …

… cetuximab for loco regionally advanced and metastatic/recurrent squamous cell carcinoma
of head and neck. Only published studies in English between 1990 and 2016 were included. …

… CT plus cetuximab (n=222) or CT alone (n=220) for 18 weeks (6 x 3-week cycles). Results:
A total of 100 pts in the cetuximab arm who had at least stable disease received cetuximab …

… Chemoradiotherapy for head and neck cancer (SCCHN) is challenging in elderly, multi-morbid
patients. Radioimmunotherapy (RIT) with cetuximab provides an option to enhance …

… Cetuximab and docetaxel have single-agent activity in squamous cell carcinoma of the head
and neck … for a maximum of 6 cycles and concomitant cetuximab 250 mg/m 2 weekly until …

… for at least 6 months on cetuximab therapy harbored tumors with squamous cell histology. In
… patients treated with cetuximab harboring adenosquamous or adenocarcinoma of the cervix …

… This article presents a summary of the ERG report for the STA of cetuximab for recurrent
and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), and the subsequent …

… with head and neck squamous cell carcinoma, the KRAS-variant predicted a significant,
positive response to cetuximab… biomarker of cetuximab response in patients with head and neck …

… Updated survival figures confirmed efficacy of RT plus cetuximab (RT + C) compared to …
cetuximab in 2004 for the treatment of patients with squamous cell cancer of the head and neck …